View the NewsRx Library

Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Google 2009 PageRank: #2 Among Top Health News and Media Publications

Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology

Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals

Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This site complies with the HONcode standard for trustworthy health information:
verify here.

Search Results for Shire Plc

Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20 Next >

Refine Search

Display Mode: Context | Summary

FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity

2009 NOV 9 ... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces ...

Subject: Shire Plc

Price: $3.00

FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease

2009 NOV 16 ... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced ...

Subject: Gaucher Disease

Price: $3.00

MZ Announces Agreement with the Netherlands Society for Investor Relations NEVIR for the European Event of 2010 IR Global Rankings

2009 NOV 2 ... Electronics (NYSE:PHG); Sampo Plc (NASDAQ:SAMAS); Sanofi-Aventis (EURONEXT: SAN); Shire Pharmaceuticals Group ; Stora Enso (OMX: STERV); Strabag (WBAG: STR); Swiss Life (SIX: ...

Subject: MZ Consult Ny Llc

Price: $3.00

New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners' ADHD R

2009 NOV 9 ... Shire plc , the global specialty biopharmaceutical company, announced new study results on ...

Subject: Attention Deficit Hyperactivity Disorder

Price: $3.00

New Shire Board Member

2009 NOV 16 ... The Board of Directors of Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that Mr David Stout joined the Board as a Non ...

Subject: Pharmaceuticals

Price: $3.00

New Study on Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII Shows Administration of Vyvanse Through Two Different Routes Demonstrated a Similar Pharmacokinetic Profile

2009 NOV 2 ... Shire plc , the global specialty biopharmaceutical company, announced new data about the ...

Subject: Pharmacokinetics

Price: $3.00

Once-Daily INTUNIV guanfacine Extended Release Tablets Now Available in Pharmacies Nationwide

2009 NOV 28 ... Shire plc , the global specialty biopharmaceutical company, announced the availability of ...

Subject: Shire plc

Price: $3.00

Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide

2009 NOV 23 ... Shire plc , the global specialty biopharmaceutical company, announced the availability of ...

Subject: Pediatrics

Price: $3.00

Seaside Therapeutics Recruits Industry Veterans to Accelerate Development of Candidates for Autism and Fragile X Syndrome

2009 NOV 1 ... life science companies, including Transkaryotic Therapies, Inc. (later acquired by Shire plc), CytoTherapeutics, Inc. and Omnisonics Medical Technologies, Inc. Dr. ...

Subject: Seaside Therapeutics

Price: $3.00

Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)

2009 NOV 1 ... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces ...

Subject: Generics

Price: $3.00

Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants

2009 NOV 30 ... Shire plc , the global specialty biopharmaceutical company, announced new study results on ...

Subject: Attention Deficit Hyperactivity Disorder

Price: $3.00

Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting

2009 NOV 9 ... Shire plc , the global specialty biopharmaceutical company, presented the results of three ...

Subject: Regulatory Actions

Price: $3.00

Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII

2009 NOV 23 ... Shire plc , the global specialty biopharmaceutical company, announced findings from a post hoc ...

Subject: Pediatrics

Price: $3.00

Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD

2009 NOV 16 ... Shire plc , the global specialty biopharmaceutical company, announced findings at a major medical ...

Subject: Tics

Price: $3.00

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL for Fabry Disease With U.S. FDA

2009 NOV 2 ... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, ...

Subject: Shire Plc

Price: $3.00

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA

2009 NOV 2 ... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces ...

Subject: Fabry Disease

Price: $3.00

Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30

2009 NOV 9 ... Shire plc , the global specialty biopharmaceutical company, announced that it will present key ...

Subject: Attention Deficit Hyperactivity Disorder

Price: $3.00

Results 1 - 20 Next >


Home \| Free Newsletters \| Products \| Article Library \| About Us \| Contact \| Privacy Policy \| Search \| Visit VerticalNews.com Copyright © 2009 NewsRx